Since patients with HER2/neu+ ALL were significantly younger than patients with HER2/neu− ALL, we also adjusted analyses of OS and DFS for the age groups below and above 40, 50 and 60 years. Here, ERBB2 is linked to acute lymphoblastic leukemia.